ClinicalTrials.gg
RecruitingNCT07634081Updated Jun 11, 2026

Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC

An observational study in Mpox, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Democratic Republic of the Congo. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started May 2026; still recruiting 6 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Sex
All
01

Study summary

The objective of this prospective paired diagnostic comparison study is to evaluate the diagnostic yield and field applicability of SDS-EDTA-treated chromatography paper strips for the collection, transport, and laboratory detection of mpox virus compared with the routine swab-based sampling method under field conditions in the Democratic Republic of the Congo (DRC).

The study is conducted among patients with suspected mpox infection presenting to healthcare facilities in South Kivu, DRC. For each participant, paired samples are collected simultaneously using the standard swab method and the SDS-EDTA strip method. Samples are analyzed using locally available molecular diagnostic platforms.

02

Conditions studied

  • Mpox

Browse trials for

03

In context

Mpox, Monkeypox

72 studies on the registry are indexed under Mpox, Monkeypox; 30 are open to participants now.

This study's planned enrollment of 150 is below the median of 224 across 34 observational studies indexed under Mpox, Monkeypox.

Browse Mpox, Monkeypox studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with suspected mpox infection in South Kivu, DRC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting with clinical signs compatible with mpox infection according to national case definition.
  • Written obtained.
  • Presence of at least two skin lesions in a similar stage of evolution suitable for paired sampling.

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to provide .
  • Presence of only one suitable lesion for sampling.
  • Lesions at markedly different stages of evolution.
  • Inability to safely obtain paired samples.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Interventions

  • Diagnostic testSDS-EDTA-treated chromatography strip

    Chromatography strip treated with a buffer containing SDS and EDTA. SDS inactivates the virus and reduces biosafety constraints during transport, while EDTA stabilizes nucleic acids and reduces dependence on cold-chain conditions.

06

What researchers measure

Primary outcomes

  1. Paired difference in mpox positivity between SDS-EDTA strip samples and routine swab samples.

    Time frame: Laboratory analysis of collected samples up to 6 months after collection

07

Study locations

1 of 1 sites recruiting
  • Miti-Murhesa General Referral Hospital and affiliated healthcare facilities in South Kivu
    Bukavu, Democratic Republic of the Congo
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07634081
Collaborators
Rwanda Biomedical Centre, Erasmus Medical Center, Stansile, Rwanda, Division Provinciale de la Santé, Bukavu, Centre de Recherche en Sciences Naturelles, South Kivu
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
May 1, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Jun 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion